1 day Ago By ABMN Staff
American Century Companies Inc. increased its holdings in Viking Therapeutics, Inc. ( NASDAQ:VKTX – Free Report ) by 9.
4% in the 4th quarter, Holdings Channel reports. The fund owned 301,582 shares of the biotechnology company’s stock after buying an additional 25,824 shares during the quarter. American Century Companies Inc.
’s holdings in Viking Therapeutics were worth $12,136,000 as of its most recent SEC filing. Other large investors also recently bought and sold shares of the company. Blue Trust Inc.
grew its holdings in Viking Therapeutics by 75.9% in the fourth quarter. Blue Trust Inc.
now owns 716 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 309 shares during the period. YANKCOM Partnership purchased a new stake in shares of Viking Therapeutics in the 4th quarter worth approximately $33,000. S.
A. Mason LLC boosted its holdings in Viking Therapeutics by 20.0% in the fourth quarter.
S.A. Mason LLC now owns 1,800 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 300 shares in the last quarter.
Wolff Wiese Magana LLC bought a new position in Viking Therapeutics in the 4th quarter worth about $75,000. Finally, AlphaQuest LLC grew its holdings in shares of Viking Therapeutics by 79.4% during the fourth quarter.
AlphaQuest LLC now owns 1,938 shares of the biotechnology company’s stock valued at $78,000 after buying an additional 858 shares during the last quarter. 76.03% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades VKTX has been the topic of several recent analyst reports. Raymond James increased their price objective on Viking Therapeutics from $122.00 to $125.
00 and gave the company a “strong-buy” rating in a research report on Thursday, February 6th. Citigroup assumed coverage on shares of Viking Therapeutics in a research note on Friday, February 7th. They issued a “neutral” rating and a $38.
00 price target for the company. B. Riley restated a “buy” rating and set a $96.
00 price objective (down previously from $109.00) on shares of Viking Therapeutics in a research report on Friday, February 7th. HC Wainwright reaffirmed a “buy” rating and issued a $102.
00 target price on shares of Viking Therapeutics in a research report on Wednesday, March 26th. Finally, Piper Sandler lowered their price target on Viking Therapeutics from $74.00 to $71.
00 and set an “overweight” rating on the stock in a report on Thursday, February 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Viking Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $95.
18. Viking Therapeutics Stock Down 1.0 % VKTX stock opened at $23.
91 on Wednesday. The business’s 50-day moving average price is $29.94 and its 200-day moving average price is $45.
92. The stock has a market cap of $2.68 billion, a P/E ratio of -23.
91 and a beta of 0.90. Viking Therapeutics, Inc.
has a twelve month low of $23.27 and a twelve month high of $81.86.
Viking Therapeutics ( NASDAQ:VKTX – Get Free Report ) last posted its quarterly earnings results on Wednesday, February 5th. The biotechnology company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.
27) by ($0.05). During the same period last year, the company posted ($0.
25) EPS. On average, equities research analysts expect that Viking Therapeutics, Inc. will post -1.
56 earnings per share for the current fiscal year. Insider Buying and Selling In other Viking Therapeutics news, COO Marianna Mancini sold 54,215 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $42.
75, for a total value of $2,317,691.25. Following the completion of the transaction, the chief operating officer now directly owns 374,134 shares in the company, valued at $15,994,228.
50. This represents a 12.66 % decrease in their position.
The transaction was disclosed in a document filed with the SEC, which is available through the SEC website . Also, CEO Brian Lian sold 194,490 shares of Viking Therapeutics stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $42.
75, for a total transaction of $8,314,447.50. Following the sale, the chief executive officer now owns 2,366,570 shares in the company, valued at approximately $101,170,867.
50. The trade was a 7.59 % decrease in their position.
The disclosure for this sale can be found here . In the last quarter, insiders sold 299,014 shares of company stock valued at $12,782,849. Company insiders own 4.
70% of the company’s stock. Viking Therapeutics Profile ( Free Report ) Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Featured Articles Want to see what other hedge funds are holding VKTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viking Therapeutics, Inc. ( NASDAQ:VKTX – Free Report ).
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
_8.jpg?itok=wp-xhXRB)
